What combination therapy with a statin, if any, would you recommend? (Q37812296)

23 August 2017

What combination therapy with a statin, if any, would you recommend? (English)

1 reference

23 August 2017

Carlos A Dujovne

1

1 reference

23 August 2017

Craig D Williams

series ordinal

2

1 reference

23 August 2017

Matthew K Ito

series ordinal

3

1 reference

23 August 2017

language of work or name

1 reference

1 February 2011

1 reference

Current Atherosclerosis Reports

23 August 2017

1 reference

23 August 2017

13

1 reference

23 August 2017

1

1 reference

23 August 2017

12-22

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-010-0150-3

23 August 2017

0 references

cites work

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Nonoptimal high-density lipoprotein cholesterol levels are highly prevalent in patients presenting with acute coronary syndromes and well-controlled low-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

The role of oxidized LDL in the atherogenic process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Effectiveness of ezetimibe in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Simvastatin with or without ezetimibe in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Statin therapy with ezetimibe or niacin in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Analyses of cancer data from three ezetimibe trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-010-0150-3

Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia

21 January 2018

1 reference

12 December 2020

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

12 December 2020

Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin

1 reference

12 December 2020

Effects of a low saturated fat, low cholesterol fish oil supplement in hypertriglyceridemic patients. A placebo-controlled trial

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients

1 reference

12 December 2020

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

1 reference

12 December 2020

Standards of medical care in diabetes--2010.

1 reference

12 December 2020

Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up

1 reference

12 December 2020

Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial

1 reference

12 December 2020

10.1007/S11883-010-0150-3

Identifiers

DOI

1 reference

23 August 2017

1 reference